SAN DIEGO., Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today announced that the U.S. FDA Center for Biologics Evaluation and ...
The Generx (TM) (alferminogene tadenovec, Ad5FGF-4) product candidate represents a new class of cardiovascular biologics that is being developed to leverage the body's natural healing processes in ...
Cardium Therapeutics announced that it has received clearance from the Russian Ministry of Health and Social Development to commence a phase III registration study for the company's Generx ...
Generx is an interventional cardiology-focused product candidate that is being developed to offer a one-time, non-surgical option for the treatment of a medical condition termed cardiac microvascular ...
SAN DIEGO, April 7, 2015 /PRNewswire/ -- Taxus Cardium Pharmaceuticals Group Inc. (trading symbol: CRXM) today announced that it has entered into a binding term sheet with Dr. Reddy's Laboratories Ltd ...
Cardium Therapeutics has reported advancements of its two key biologics products, its Generx candidate for the potential treatment of coronary artery disease, and Excellagen advanced wound care ...
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors. Cardium Therapeutics has developed a unique portfolio of businesses and product opportunities in the fields of ...
SAN DIEGO, CA – May 16, 2012 – Cardium Therapeutics (NYSE Amex: CXM) today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting ...
SAN DIEGO, Angionetics Inc., a majority-owned subsidiary of Taxus Cardium Pharmaceuticals Group Inc. (Trading Symbol: CRXM), today reported that the FDA has granted Fast Track designation for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results